SCHEMBL22024646

SCHEMBL22024646

Cc1ccc(C(=O)Nc2cc(N3CCN(C)CC3)cc(C(F)(F)F)c2)cc1Nc1nc(-c2ccncc2)nc2c1ccn2C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 2/20 0.61
▸ HCK P08631 2/20 0.56
▸ BTK Q06187 2/20 0.56
▸ NR2C2 P49116 1/20 0.56
▸ LYN P07948 2/20 0.56
▸ CSF1R P07333 1/20 0.56
▸ KIT P10721 1/20 0.56
▸ BRAF P15056 15/20 0.55
▸ MAP4K2 Q12851 3/20 0.52
▸ MAP3K7 O43318 2/20 0.52
▸ ESYT2 A0FGR8 1/20 0.51
▸ PLEKHG3 A1L390 1/20 0.51
▸ NBAS A2RRP1 1/20 0.51
▸ CNOT1 A5YKK6 1/20 0.51
▸ TBKBP1 A7MCY6 1/20 0.51
▸ MYO1G B0I1T2 1/20 0.51
▸ AGPS O00116 1/20 0.51
▸ MYO1F O00160 1/20 0.51
▸ SNAP23 O00161 1/20 0.51
▸ AP3B1 O00203 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22024644 0.92 ABL1 (0.69) ABL1HCKBTKNR2C2LYN
SCHEMBL22024645 0.85 BRAF (0.68) ABL1HCKBTKLYNCSF1R
SCHEMBL22025311 0.82 BRAF (0.68) ABL1LYNCSF1RKITBRAF
SCHEMBL18804561 0.78 DDR1 (0.81) ABL1HCKBTKLYNCSF1R
SCHEMBL22025379 0.77 ABL1 (0.69) ABL1HCKBTKNR2C2LYN
SCHEMBL10106165 0.75 BRAF (0.75) BRAF
SCHEMBL1653558 0.75 ABL1 (0.79) ABL1HCKBTKNR2C2LYN
SCHEMBL10106131 0.74 BRAF (0.69) ABL1LYNCSF1RKITBRAF
SCHEMBL4697696 0.74 BRAF (0.86) ABL1HCKBTKLYNCSF1R
SCHEMBL22025467 0.74 ABL1 (0.71) ABL1LYNCSF1RKITBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352354-B2 Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof XIAMEN UNIVERSITY (CN) 2022-06-07 — — US disclosed
US-20200165246-A1 SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-05-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352354-B2 Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof PIKFYVE, PIK3CA, PIK3C2A ABL1 1429/4885HCK 740/4885BTK 594/4885
US-20200165246-A1 SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF PIKFYVE, PIK3CA, PIK3C2A ABL1 1429/4885HCK 740/4885BTK 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback